Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00045201 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Amendment history

The 50 most recent of 149 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Minor

    Completion pushed from Aug 22, 2026 to Aug 13, 2027

    Study Statusv149

  2. Minor

    39 amendments

    39 re-verifications since 2026-02-14, no change to tracked fields

    v110-v148

  3. Minor

    Completion date: Aug 22, 2025 to Aug 22, 2026

    Study Statusv109

  4. Minor

    2 amendments

    2 re-verifications since 2025-02-19, no change to tracked fields

    v107-v108

  5. Minor

    Completion date: Aug 22, 2024 to Aug 22, 2025

    Study Statusv106

Show 6 earlier versions

  1. Minor

    4 amendments

    4 re-verifications since 2023-09-12, no change to tracked fields

    v102-v105

  2. Minor

    Completion date: Aug 22, 2024

    Study Statusv101

  3. Minor

    Study Status

    Re-verified, no change to tracked fields

    v100

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase I trial to study the effectiveness of combining erlotinib hydrochloride with irinotecan hydrochloride in treating patients who have advanced solid tumors. Erlotinib hydrochloride may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib hydrochloride and chemotherapy may kill more tumor cells.
Trial Details
NCT Number NCT00045201
Lead Sponsor National Cancer Institute (NCI)
Conditions Adult Solid Neoplasm
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov